CN116376068B - 一种植酸交联淀粉-蛋白质复合物协同稳定的双重乳液及在医药领域的应用 - Google Patents
一种植酸交联淀粉-蛋白质复合物协同稳定的双重乳液及在医药领域的应用 Download PDFInfo
- Publication number
- CN116376068B CN116376068B CN202310359592.5A CN202310359592A CN116376068B CN 116376068 B CN116376068 B CN 116376068B CN 202310359592 A CN202310359592 A CN 202310359592A CN 116376068 B CN116376068 B CN 116376068B
- Authority
- CN
- China
- Prior art keywords
- phytic acid
- starch
- double emulsion
- emulsion
- dispersion liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 146
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 title claims abstract description 90
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 title claims abstract description 90
- 235000002949 phytic acid Nutrition 0.000 title claims abstract description 90
- 229940068041 phytic acid Drugs 0.000 title claims abstract description 90
- 239000000467 phytic acid Substances 0.000 title claims abstract description 90
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 title abstract description 9
- 229920002472 Starch Polymers 0.000 claims abstract description 77
- 235000019698 starch Nutrition 0.000 claims abstract description 77
- 239000006185 dispersion Substances 0.000 claims abstract description 76
- 239000008107 starch Substances 0.000 claims abstract description 76
- 239000007788 liquid Substances 0.000 claims abstract description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 44
- 239000002356 single layer Substances 0.000 claims abstract description 36
- 238000003756 stirring Methods 0.000 claims abstract description 36
- 238000002156 mixing Methods 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 239000002245 particle Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 15
- 229920000223 polyglycerol Polymers 0.000 claims abstract description 13
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 claims abstract description 13
- 229940066675 ricinoleate Drugs 0.000 claims abstract description 13
- 238000004945 emulsification Methods 0.000 claims abstract description 9
- 239000012071 phase Substances 0.000 claims description 84
- 229920000881 Modified starch Polymers 0.000 claims description 59
- 239000004368 Modified starch Substances 0.000 claims description 59
- 235000019426 modified starch Nutrition 0.000 claims description 59
- 239000008187 granular material Substances 0.000 claims description 36
- 239000002244 precipitate Substances 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000008346 aqueous phase Substances 0.000 claims description 9
- 238000010008 shearing Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 230000003287 optical effect Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 52
- 235000019198 oils Nutrition 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 38
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 18
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 12
- 240000003183 Manihot esculenta Species 0.000 description 10
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 235000012754 curcumin Nutrition 0.000 description 9
- 239000004148 curcumin Substances 0.000 description 9
- 229940109262 curcumin Drugs 0.000 description 9
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 8
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 8
- 235000005487 catechin Nutrition 0.000 description 8
- 229950001002 cianidanol Drugs 0.000 description 8
- 239000002285 corn oil Substances 0.000 description 8
- 235000005687 corn oil Nutrition 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 239000011246 composite particle Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009775 high-speed stirring Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IOAISUCAQCEHTA-UHFFFAOYSA-N 5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC=C(C)C=C1O.CC(C)C1=CC=C(C)C=C1O IOAISUCAQCEHTA-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 239000010507 melon oil Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960002194 oseltamivir phosphate Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000005501 phase interface Effects 0.000 description 1
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019465 surimi Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/05—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media from solid polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/612—By organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2303/00—Characterised by the use of starch, amylose or amylopectin or of their derivatives or degradation products
- C08J2303/04—Starch derivatives
- C08J2303/06—Esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2489/00—Characterised by the use of proteins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种植酸交联淀粉‑蛋白质复合物协同稳定的双重乳液及在医药领域的应用,属于乳化技术领域、医药配制品领域。本发明先制备含有经过植酸改性后淀粉颗粒,并将其及蛋白质分别溶于水形成分散液,按比例混合后形成水相,再制备含有聚甘油蓖麻醇酯(PGPR)的油作为油相,通过高能乳化法制备单层乳液,然后将单层乳液加入到油相中,经低速搅拌处理得到稳定的双重乳液凝胶。本发明的植酸交联淀粉‑蛋白质复合物协同稳定的双重乳液,具有稳定的油水界面和光学稳定性,制备方法简单,利于实现工业化生产,在功能活性成分的封装递送等方面具有广阔的市场前景。
Description
技术领域
本发明涉及一种植酸交联淀粉-蛋白质复合物协同稳定的双重乳液及在医药领域的应用,属于乳化技术领域、医药配制品领域。
背景技术
双重乳液具有特殊的“三相两界面”结构,可溶解不同特性的活性成分,保护其免受胃肠道环境破坏并对其起到缓控释的调节作用,因此在功能性成分的运载递送体系方面具有独特优势,在药剂、食品等领域中具有重要的应用。考虑到合成高分子载体材料存在潜在的安全性问题,开发绿色、安全的食品级双乳液运载体系已成为新的趋势。蛋白质具有良好的乳化性,因此常被作为乳化剂,然而蛋白质需要提取的成本高,并且具有一定的致敏性,在不同pH下的稳定性有较大差异。因此,有必要降低蛋白质稳定的乳液中蛋白质的用量。
淀粉是一种来源广泛、价格低廉、生物相容性好的天然高分子,在体内易被降解成葡萄糖等小分子物质,被人体很好的吸收,所以选用淀粉作为功能因子递送和缓释的载体材料具有很大优势,但其乳化效果欠佳,制备出的乳液体系很难确保油滴内部水滴的稳定。近年来,可食用颗粒型乳化剂的研究引起了人们广大的兴趣,其能够不可逆的吸附于油水界面,形成界面层,赋予乳液稳定性。用可食用胶体颗粒代替至少一种类型的表面活性剂分子稳定双层乳液界面的概念为双层乳液的稳定提供了新的方法。但如何获得稳定的淀粉基双乳并最大程度上减少小分子乳化剂的使用,也是需要解决的问题。
发明内容
[技术问题]
现有的双重乳液体系,至少存在如下一个技术问题:(1)稳定性差;(2)制备方法复杂;(3)成本高;(4)需要用到异臭物质;(5)存在安全性方面的隐患等。
[技术方案]
为了解决上述问题,本发明提供一种简单、便捷的方法用于制备双重乳液,仅通过一步乳化即可制得双重乳液,植酸改性淀粉后的颗粒粉和与蛋白质复合,既作内水相又作外水相,制备过程耗时更短、耗能更低。本发明制备的双重乳液具有良好的稳定性,蛋白用量低,不含有吐温20等异臭物质。本发明方法及双重乳液,利于实现工业化生产、扩大双层乳液在医药药剂、化妆品、食品工业上的应用。
本发明的双重乳液的制备方法,是以含有经过植酸改性后淀粉颗粒和蛋白质分散液形成的水相,以含有聚甘油蓖麻醇酯(PGPR)的油为油相,通过高能乳化法制备单层乳液;然后将单层乳液逐滴缓慢加入到油相中,经<8000rpm的条件处理得到稳定的双重乳液。
本发明的制备方法包括如下:
(1)制备植酸改性淀粉:淀粉加入水中制备原淀粉分散液(即淀粉颗粒悬浮液),在原淀粉分散液中加入植酸进行反应;植酸的质量是淀粉干基质量的0.01~4wt%;一段时间后终止反应,得到植酸改性淀粉分散液;
(2)制备植酸改性淀粉颗粒:将上一步得到的分散液进行离心、洗涤,沉淀物烘干后粉碎,获得磷酸化的淀粉颗粒粉末,即植酸改性淀粉颗粒;
(3)制备水相:将步骤(2)得到的植酸改性淀粉颗粒和蛋白质分别分散于水中,将植酸改性淀粉颗粒分散液进行糊化处理;水相为植酸改性淀粉颗粒分散液(糊化后)和蛋白质分散液的混合液,水相中植酸改性淀粉颗粒分散液和蛋白质分散液的体积比为10:9~10:0.1;
(4)制备油相:将聚甘油蓖麻醇酯与油混合搅拌,完全溶解后获得油相;其中,所述聚甘油蓖麻醇酯的添加质量为油质量的0.5~7%;
(5)制备单层乳液:将油相与水相混合,通过高能乳化法制备单层乳液;水相和油相之间的体积比为5:5~9:1;
(6)制备双重乳液:将单层乳液逐滴缓慢加入到油相,然后进行1000~6000rpm的低速搅拌或剪切处理,制备得到稳定的双重乳液;其中,所述单层乳液与油相之间的体积比为1:9-5:5。
在一种实施方式中,所述步骤(1)中原淀粉分散液为20~60wt%。可选地,所述步骤(1)中,反应体系温度为40~55℃;反应的过程中控制体系的pH恒定在7~7.5之间;反应的时间为1-9h。
在一种实施方式中,所述步骤(1)中,植酸是通过逐滴加入的方式加入到原淀粉分散液中。
在一种实施方式中,所述步骤(1)中,终止反应是通过调节pH值至6.5以终止。可选地,使用1mol/L的稀盐酸来调节pH。
在一种实施方式中,所述步骤(2)中,植酸改性淀粉分散液于3500rpm离心15min;可选地,用水和乙醇洗涤充分沉淀物,以去除杂质。
在一种实施方式中,步骤(3)中植酸改性淀粉颗粒分散液是在90℃糊化30min。
在一种实施方式中,步骤(3)中,植酸改性淀粉颗粒分散液中的浓度为0.5~7wt%,蛋白质分散液的浓度为0.5~7wt%。可选地,植酸改性淀粉颗粒分散液浓度为1~5wt%;所述蛋白质分散液浓度为1~3wt%。
在一种实施方式中,所述步骤(3)中,淀粉颗粒分散液和蛋白分散液按照体积比为10:9~10:0.7。
在一种实施方式中,所述步骤(3)中,植酸改性淀粉颗粒分散液的浓度为3%wt,蛋白质分散液的浓度为3%wt;淀粉颗粒分散液和蛋白分散液按照体积比为10:1混合得到水相。
在一种实施方式中,步骤(4)中混合搅拌时间为30~60min。
在一种实施方式中,步骤(4)的搅拌温度为45~65℃。
在一种实施方式中,所述步骤(5)中,高能乳化法是指用高速搅拌、高压均质或超声等方法。高速搅拌、高压均质或超声等方法提供大量的能量,通过拉伸和碰撞使大液滴破裂成小液滴,从而形成纳米乳液。
在一种实施方式中,步骤(5)是使用高速均质制备单层乳液,均质速度为8000~20000rpm,均质时间为1~2min。
在一种实施方式中,所述步骤(5)中,水相和油相之间的体积比为5:5~7:3;可选地,水相和油相之间的体积比为7:3。
在一种实施方式中,步骤(6)中所述单层乳液与油相之间的体积比为3:2。
在一种实施方式中,步骤(6)是在1500rpm下低速搅拌,制备得到双重乳液。
在一种实施方式中,步骤(6)的低速剪切或低速搅拌处理时,剪切时间为5~10min。
在一种实施方式中,所述<8000rpm是在1000~6000rpm。
在一种实施方式中,所述淀粉包括木薯淀粉、玉米淀粉、大米淀粉、豌豆淀粉、莲藕淀粉、马铃薯淀粉等不同晶型淀粉的一种或几种。
在一种实施方式中,所述蛋白质为乳清分离蛋白、乳铁蛋白、酪蛋白、血清蛋白、卵蛋白、鱼糜蛋白、明胶、胶原蛋白、大豆蛋白、花生蛋白中的一种或多种。
在一种实施方式中,所述油为玉米油、芝麻油、大豆油、花生油、菜籽油、橄榄油、中链甘油三酯、亚麻籽油、葵花籽油、棉籽油、瓜子油中的一种或多种。
在一种实施方式中,所述双重乳液的制备方法,具体包括如下:
(1)利用植酸改性淀粉
先制备原淀粉分散液:将淀粉溶于去离子水,搅拌至充分溶解,形成淀粉分散液(淀粉颗粒悬浮液),所述淀粉和去离子水的质量体积比为20~60g:100mL,用NaOH溶液将淀粉乳的pH调至7~7.5,氢氧化钠溶液的浓度为1mol/L;将淀粉乳置于45~55℃恒温水浴锅内磁力搅拌加热,所述的磁力搅拌速度为300~600rpm;
利用植酸制备改性淀粉:
向步骤(1)中的淀粉分散液中逐滴加入植酸,所述植酸的质量是基于淀粉质量的0.01~4%,在反应过程中不断滴加1mol/LNaOH溶液控制体系的pH值恒定在7~7.5之间,所述氢氧化钠溶液的浓度为1mol/L;反应1~9h后,用稀盐酸将体系的pH值调节至6.5以终止反应进行,所述稀盐酸的浓度为1mol/L,恒温搅拌温度范围为45~55℃;
(2)制备植酸改性淀粉颗粒粉末
将步骤(1)所得的植酸改性淀粉分散液于3500rpm离心15min,分别用水和乙醇洗涤充分沉淀物,以去除杂质;将沉淀物于40~60℃烘干12~24h并研磨粉碎,用200目过筛获得磷酸化的淀粉颗粒粉末,即植酸改性淀粉颗粒粉末;
(3)确认水相:将步骤(2)得到的植酸改性淀粉颗粒粉末及蛋白质分别分散于蒸馏水中,分别得到0.5~7wt%的植酸改性淀粉分散液和0~7wt%的蛋白质的水相分散液,将淀粉分散液于90℃糊化30min;水相中,含有糊化后的植酸改性淀粉颗粒分散液和蛋白质分散液的体积比为10:9~10:0.1;
(4)制备油相
将聚甘油蓖麻醇酯与玉米油混合搅拌30~60min,完全溶解后获得油相;其中,所述聚甘油蓖麻醇酯的添加质量为玉米油质量的0.5~7%,搅拌温度为45~65℃;
(5)制备单层乳液
将步骤(4)得到的油相与水相混合后立即进行高速均质,得到单层乳液;其中,水相和油相之间的体积比为9:1~5:5;均质速度为8000~20000rpm,均质时间为1~2min;
(6)制备双重乳液
将单层乳液逐滴缓慢加入到油相,然后进行1000~6000rpm的低速搅拌或剪切处理,制备得到稳定的双重乳液;其中,所述单层乳液与油相之间的体积比为1:9-5:5。低速搅拌或剪切的时间为5~10min。
本发明还提供利用上述方法制备得到的双重乳液。
本发明提供一种运载递送体系,所述运载递送体系利用本发明的双重乳液;运载递送的物质位于所述双重乳液的水相和/或油相中。
在一种实施方式中,所述运载递送的物质为亲水相或者亲油物质,分别位于双重乳液的水相或者油相中。
在一种实施方式中,所述运载因子,可以是百里香酚(2-异丙基-5-甲基苯酚)、磷酸奥司他韦、布洛芬、阿霉素等用于生物医药领域。
在一种实施方式中,所述运载因子,可以是水溶性物质,添加在水相中,比如花青素、茶多酚、维生素C;也可以是脂溶性物质,添加在油相中,比如姜黄素、白藜芦醇、虾青素、肉桂精油,用于食品领域。
在一种实施方式中,所述运载因子,可以是褪黑激素、生育乙酸酯、生育酚、维生素E,用于防晒、美白、抗衰老、皮肤护理等化妆品领域。
[有益效果]
(1)本发明采用简单、便捷的方法制备双重乳液,制备过程耗时更短、耗能更低,适合工业化应用;
(2)本发明利用植酸对淀粉及蛋白质的双交联作用,维持淀粉基双重乳液体系的稳定;不仅不需要用到异臭物质,也最大程度上减少小分子乳化剂的使用;而且添加的蛋白质用量极少、成本低。
(3)本发明的双重乳液,制备和使用都很安全,利于扩大双层乳液在医药药剂、化妆品、食品工业上的应用;本发明中用到的植酸是一种天然物质,安全无毒,常被用作食品添加剂;本发明利用的植酸,含有一个肌醇和六个磷酸基团,能与多价阳离子和带正电的蛋白质通过静电结合形成复合物,也能与淀粉分子共价结合生成磷酸二酯键。
(4)本发明利用植酸与淀粉及蛋白质交联反应,协同稳定了双重乳液内外水油相之间的界面平衡,制备的双重乳液具有稳定的油水界面和光学稳定性,克服了现有技术中对于利用传统淀粉稳定乳液效果差的缺陷。本发明中植酸改性淀粉能够在内外层油水表面进行液滴吸附,通过形成致密的界面膜抑制液滴的聚结和Ostwald熟化,利于双重乳液的稳定(7天)。本发明中制备的可食用的双乳液粒径大小为25~60μm。
(5)本发明构建的双重乳液具有良好的稳定性,稳定的三相体系网络能够使得生物活性物质在胃肠道的稳定性得到提高。即本发明的双重乳液在消化道上部停留时乳液表面受侵蚀和溶胀作用边向消化道下部移动,内水相与油相负载的功能因子由于进一步受侵蚀而在小肠部位持续释放。
附图说明
图1为植酸交联淀粉-蛋白质复合稳定双重乳液的制备示意图;
图2为实施例1得到的植酸改性淀粉-蛋白质复合颗粒稳定的双重乳液的激光共聚焦电镜结果;
图3为实施例2得到的植酸改性淀粉-蛋白质复合颗粒稳定的双重乳液的光学显微镜结果;
图4为实施例2得到的植酸改性淀粉-蛋白质复合颗粒稳定的双重乳液的表观图片及光学显微镜结果。
具体实施方式
以下对本发明的优选实施例进行说明,应当理解实施例是为了更好地解释本发明,不用于限制本发明。
如图1所示,为本发明的植酸交联淀粉-蛋白质复合稳定双重乳液的制备示意图。
测试方法:
微观结构:将10μL双重乳液样品小心置于玻璃片上,覆以盖玻片,利用光学显微镜在40×下观察。
粒度大小:用蒸馏水稀释200倍。使用动态光散射(DLS)和纳米粒度仪测定样品的平均粒径,所有测量均进行三次。
激光共聚焦显微镜:用生物激光共聚焦显微镜观察水凝胶或乳液凝胶的微观分布。尼罗红和FITC分别用作油相和蛋白质相的荧光染料。将双重乳液(3μL)转移到载玻片上。将尼罗红(0.1wt%,DMSO)和FITC(0.1wt%,丙酮)按1:1的比例混合约15min,然后将6μL混合荧光染料溶液添加到每个样品中,盖上盖玻片。在633nm和488nm的激发波长下,用40×放大镜拍摄每个样品代表区域的图像,由He-Ne激光器提供。
稳定性:从观察表观是否分层和/或微观图像分析。
实施例1不同植酸改性淀粉浓度对双重乳液稳定性的影响
一种植酸改性淀粉-蛋白质复合物颗粒协同稳定的双重乳液及其制备方法,包括如下步骤:
(1)称取木薯淀粉30g制备30wt%的淀粉分散液,搅拌至均匀后,将淀粉乳(淀粉分散液)pH调至7.0;加入植酸(淀粉干重的2%),在600rpm转速下,将淀粉乳置于45~55℃恒温水浴锅内磁力搅拌5h,利用1mol/LNaOH和维持体系的pH7.0保持恒定,最后将体系的pH值调节至6.5以终止反应。
(2)将上一步的产物,于3500rpm离心15min,将沉淀物用水和乙醇洗涤充分,直至上清液与AgNO3反应后无白色沉淀,以确保除去植酸改性淀粉中的氯离子等杂质;将沉淀物于50℃烘干24h并研磨粉碎,获得磷酸化的木薯淀粉颗粒,即植酸改性的淀粉颗粒。
(3)用蒸馏水分散,分别制备1wt%、3wt%、5wt%的植酸改性的淀粉颗粒分散液并于90℃糊化30min,以及3wt%的蛋白质分散液,按糊化后的植酸改性的淀粉颗粒分散液与蛋白质分散液体积比10:1混合获得水相;
(4)将5%聚甘油蓖麻醇酯与玉米油混合搅拌30min,完全溶解后获得油相;
(5)将油相与含有植酸改性淀粉及蛋白质的水相按3:7混合,所得混合物立即通过高速均质机进行均质处理,制备得到单层乳液;
(6)将获得的单层型初级乳液按3:2的体积比逐滴缓慢加入到油相中,然后在1500rpm低速搅拌5min,制备得到双重乳液。
比较了不同植酸改性的淀粉颗粒分散液制备得到的双重乳液的情况,并在光学显微镜下观察,测试结果如表1和图2。
从图2可以看出:(1)均形成了双重乳液;(2)在5wt%的情况下,浓度过高,反相形成了油包水包油型双重乳液;(3)实施例1在3wt%的情况下形成的双重乳液,其微观分布更加均匀,这是双重乳液稳定的决定性因素之一。
表1
植酸改性淀粉颗粒浓度(wt%) | 稳定性 |
1 | 1h |
3 | 7天 |
5 | 2天 |
实施例2单层乳液缓慢倒入油相的搅拌速度及比例对双重乳液稳定性的影响
(1)称取木薯淀粉30g制备30wt%的淀粉分散液,搅拌至均匀后,将pH调至7.0;加入植酸(淀粉干重的2%),在600rpm转速下,置于45~55℃恒温水浴锅内磁力搅拌5h,利用1mol/L NaOH和维持体系的pH7.0保持恒定,最后将体系的pH值调节至6.5以终止反应。
(2)将上一步的产物于3500rpm离心15min,将沉淀物用水和乙醇洗涤充分,直至上清液与AgNO3反应后无白色沉淀,以确保除去植酸改性淀粉中的氯离子等杂质;将沉淀物于50℃烘干24h并研磨粉碎,获得植酸改性的淀粉颗粒。
(3)用蒸馏水分散,分别制备3wt%植酸改性的淀粉颗粒分散液并于90℃糊化30min,以及3wt%的蛋白质分散液,按糊化后的植酸改性的淀粉颗粒分散液与蛋白质分散液体积比10:1混合获得水相;
(4)将5%聚甘油蓖麻醇酯与玉米油混合搅拌30min,完全溶解后获得油相;
(5)将油相与含有植酸改性淀粉及蛋白质的水相按3:7混合,所得混合物立即通过高速均质机进行均质处理,制备得到单层乳液。
(6)将获得的单层型初级乳液按表2的不同体积比例(3:2、2:3、1:1)逐滴缓慢加入到油相中,然后在不同速度下(8000rpm、1500rpm)低速搅拌5min,制备得到双重乳液。
结果如图3-图4以及表2。
图3的左图为单层型初级乳液按照单层乳液与油相的比例3:2缓慢滴加并在1500rpm低速搅拌5min后制备得到的双重乳液,右图为单层乳液与油相的比例3:2缓慢滴加并在8000rpm低速搅拌5min后制备得到的乳液;从图3来看,单层乳液逐滴加入油相形成的双重乳液的稳定性,与搅拌或剪切速度有密切关联。实施例2形成的双重乳液在光学显微镜下可以被很清晰地观察到,但较大的剪切力会破坏原有的双重乳液结构,内外油水相界面发生重排形成了新的单层乳液,这说明单层乳液与第三相混合时的速率也会显著影响双重乳液体系的形成及稳定。
从图4中光学显微镜下可以观察到,1500rpm低速搅拌5min所形成的体系可以全部转为双重乳液,其液滴分布明显,且较为均匀。单层乳液按2:3和单层乳液按1:1添加到油相中,虽然能够形成双重乳液,但是仅存在少量或较少量双重乳液,此外,二者稳定性远不如实施例2的单层乳液与油相的比例3:2制备双重乳液的效果,说明单层乳液与第三相的比例显著影响了双重乳液的稳定性。
表2
实施例3:一种包封有阿霉素的协同稳定的双重乳液运载体系
一种运载递送体系,所述运载递送体系利用本发明的双重乳液制备得到;所述运载递送的物质为脑肿瘤治疗药物阿霉素,位于双重乳液的水相中。其具体制备如下:
一种递送脑肿瘤治疗药物阿霉素的协同稳定的双重乳液运载体系,包括如下步骤:
(1)称取木薯淀粉30g制备30wt%的淀粉分散液,搅拌至均匀后,将淀粉乳(淀粉分散液)pH调至7.0;加入植酸(淀粉干重的2%),在600rpm转速下,将淀粉乳置于45~55℃恒温水浴锅内磁力搅拌5h,利用1mol/LNaOH和维持体系的pH7.0保持恒定,最后将体系的pH值调节至6.5以终止反应。
(2)将上一步的产物,于3500rpm离心15min,将沉淀物用水和乙醇洗涤充分,直至上清液与AgNO3反应后无白色沉淀,以确保除去植酸改性淀粉中的氯离子等杂质;将沉淀物于50℃烘干24h并研磨粉碎,获得磷酸化的木薯淀粉颗粒,即植酸改性的淀粉颗粒。
(3)用蒸馏水分散并加入70μM阿霉素,分别制备3wt%的植酸改性的淀粉颗粒分散液并于90℃糊化30min,以及3wt%的蛋白质分散液,按糊化后的植酸改性的淀粉颗粒分散液与蛋白质分散液体积比10:1混合获得水相;
(4)将5%聚甘油蓖麻醇酯与玉米油混合搅拌30min,完全溶解后获得油相;
(5)将油相与含有植酸改性淀粉及蛋白质的水相按3:7混合,所得混合物立即通过高速均质机进行均质处理,制备得到单层乳液;
(6)将获得的单层型初级乳液按3:2的体积比逐滴缓慢加入到油相中,然后在1500rpm低速搅拌5min,制备得到含有脑肿瘤治疗药物阿霉素的双重乳液运载体系。
该含有脑肿瘤治疗药物阿霉素的双重乳液运载体系,较小液滴释放药物更快,因此可通过双重乳液的形貌及结构控制液滴释放阿霉素,在医药领域有巨大的发展潜力。
实施例4:一种包封有生育酚乙酸酯的协同稳定的双重乳液运载体系
一种运载递送体系,所述运载递送体系利用本发明的双重乳液制备得到;运载递送的物质位于所述双重乳液的油相中。
其具体制备如下:
一种包封递送疏水性生育酚乙酸酯的协同稳定的双重乳液运载体系,包括如下步骤:
(1)称取木薯淀粉30g制备30wt%的淀粉分散液,搅拌至均匀后,将淀粉乳(淀粉分散液)pH调至7.0;加入植酸(淀粉干重的2%),在600rpm转速下,将淀粉乳置于45~55℃恒温水浴锅内磁力搅拌5h,利用1mol/LNaOH和维持体系的pH7.0保持恒定,最后将体系的pH值调节至6.5以终止反应。
(2)将上一步的产物,于3500rpm离心15min,将沉淀物用水和乙醇洗涤充分,直至上清液与AgNO3反应后无白色沉淀,以确保除去植酸改性淀粉中的氯离子等杂质;将沉淀物于50℃烘干24h并研磨粉碎,获得磷酸化的木薯淀粉颗粒,即植酸改性的淀粉颗粒。
(3)用蒸馏水分散,分别制备3wt%的植酸改性的淀粉颗粒分散液并于90℃糊化30min,以及3wt%的蛋白质分散液,按糊化后的植酸改性的淀粉颗粒分散液与蛋白质分散液体积比10:1混合获得水相;
(4)将0.3mg/mL的生育酚乙酸酯、5%聚甘油蓖麻醇酯与玉米油混合搅拌30min,完全溶解后获得油相;
(5)将油相与含有植酸改性淀粉及蛋白质的水相按3:7混合,所得混合物立即通过高速均质机进行均质处理,制备得到单层乳液;
(6)将获得的单层型初级乳液按3:2的体积比逐滴缓慢加入到油相中,然后在1500rpm低速搅拌5min,制备得到包封有生育酚乙酸酯的双重乳液运载体系。
该包封有生育酚乙酸酯物质的淀粉基双重乳液运载体系,包封效率可达到98%以上,具有较强的紫外光照射及贮藏稳定性,可有效降低皮肤的氧化应激,用于化妆品的研制与开发。
实施例5:一种共递送疏水性姜黄素和亲水性儿茶素的协同稳定的双重乳液运载体系
一种运载递送体系,所述运载递送体系利用本发明的双重乳液制备得到;运载递送的物质位于所述双重乳液的水相和/或油相中。
在一种实施方式中,所述运载递送的物质为疏水性姜黄素和亲水性儿茶素,分别位于双重乳液的油相及水相中。
其具体制备如下:
一种共递送疏水性姜黄素和亲水性儿茶素的协同稳定的双重乳液运载体系,包括如下步骤:
(1)称取木薯淀粉30g制备30wt%的淀粉分散液,搅拌至均匀后,将淀粉乳(淀粉分散液)pH调至7.0;加入植酸(淀粉干重的2%),在600rpm转速下,将淀粉乳置于45~55℃恒温水浴锅内磁力搅拌5h,利用1mol/LNaOH和维持体系的pH7.0保持恒定,最后将体系的pH值调节至6.5以终止反应。
(2)将上一步的产物,于3500rpm离心15min,将沉淀物用水和乙醇洗涤充分,直至上清液与AgNO3反应后无白色沉淀,以确保除去植酸改性淀粉中的氯离子等杂质;将沉淀物于50℃烘干24h并研磨粉碎,获得磷酸化的木薯淀粉颗粒,即植酸改性的淀粉颗粒。
(3)用蒸馏水分散并加入750μg/mL儿茶素,分别制备3wt%的植酸改性的淀粉颗粒分散液并于90℃糊化30min,以及3wt%的蛋白质分散液,按糊化后的植酸改性的淀粉颗粒分散液与蛋白质分散液体积比10:1混合获得水相;
(4)将姜黄素(6wt%油相体积)、5%聚甘油蓖麻醇酯与玉米油混合搅拌30min,完全溶解后获得油相;
(5)将油相与含有植酸改性淀粉及蛋白质的水相按3:7混合,所得混合物立即通过高速均质机进行均质处理,制备得到单层乳液;
(6)将获得的单层型初级乳液按3:2的体积比逐滴缓慢加入到油相中,然后在1500rpm低速搅拌5min,制备得到共递送疏水性姜黄素和亲水性儿茶素的双重乳液运载体系。
该共递送疏水性姜黄素和亲水性儿茶素的双重乳液运载体系,对姜黄素的包封率可达88%,对儿茶素的包封率高达97%,此外,体外释放6h后,可释放出~50%姜黄素以及~90%儿茶素,在不增加载体材料的情况下提供更为丰富的活性营养成分,共递送的双重乳液可被广泛用于食品及营养保健品领域。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (7)
1.一种植酸交联淀粉-蛋白质复合物协同稳定的双重乳液的制备方法,其特征在于,所述制备方法包括:
(1)制备植酸改性淀粉:淀粉加入水中制备原淀粉分散液,在原淀粉分散液中加入植酸进行反应;植酸的质量是淀粉干基质量的0.01~4 wt%;一段时间后终止反应,得到植酸改性淀粉分散液;
(2)制备植酸改性淀粉颗粒:将上一步得到的分散液进行离心、洗涤,沉淀物烘干后粉碎,获得磷酸化的淀粉颗粒粉末,即植酸改性淀粉颗粒;
(3)制备水相:将步骤(2)得到的植酸改性淀粉颗粒和蛋白质分别分散于水中制备得到浓度为3% wt的植酸改性淀粉颗粒分散液、浓度为3% wt的蛋白质分散液,将植酸改性淀粉颗粒分散液进行糊化处理;水相为植酸改性淀粉颗粒分散液和蛋白质分散液的混合液,水相中植酸改性淀粉颗粒分散液和蛋白质分散液的体积比为10:1;
(4)制备油相:将聚甘油蓖麻醇酯与油混合搅拌,完全溶解后获得油相;其中,所述聚甘油蓖麻醇酯的添加质量为油质量的0.5~7%;
(5)制备单层乳液:将油相与水相混合,通过高能乳化法制备单层乳液;水相和油相之间的体积比为5:5~9:1;
(6)制备双重乳液:将单层乳液逐滴缓慢加入到油相,然后进行1500 rpm的低速搅拌或剪切处理,制备得到稳定的双重乳液;其中,所述单层乳液与油相之间的体积比为3:2。
2.根据权利要求1所述方法制备得到的双重乳液。
3.一种运载递送体系,所述运载递送体系是在权利要求1的双重乳液的制备方法中添加需要运载递送的物质;运载递送的物质位于所述双重乳液的水相和/或油相中。
4.权利要求2所述的双重乳液在制备医药药剂中的应用。
5.权利要求2所述的双重乳液在制备化妆品中的应用。
6.权利要求3所述的运载递送体系在制备医药药剂中的应用。
7.权利要求3所述的运载递送体系在制备化妆品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310359592.5A CN116376068B (zh) | 2023-04-06 | 2023-04-06 | 一种植酸交联淀粉-蛋白质复合物协同稳定的双重乳液及在医药领域的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310359592.5A CN116376068B (zh) | 2023-04-06 | 2023-04-06 | 一种植酸交联淀粉-蛋白质复合物协同稳定的双重乳液及在医药领域的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116376068A CN116376068A (zh) | 2023-07-04 |
CN116376068B true CN116376068B (zh) | 2023-09-19 |
Family
ID=86962935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310359592.5A Active CN116376068B (zh) | 2023-04-06 | 2023-04-06 | 一种植酸交联淀粉-蛋白质复合物协同稳定的双重乳液及在医药领域的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116376068B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102573785A (zh) * | 2009-07-27 | 2012-07-11 | 化工产品开发公司Seppic | 具有改善的感官性能的水包油乳液 |
CN110917137A (zh) * | 2019-11-26 | 2020-03-27 | 江南大学 | 一种醇溶蛋白纳米颗粒和淀粉纳米颗粒协同稳定的超稳定的皮克林乳液的制备方法 |
CN112120213A (zh) * | 2020-09-23 | 2020-12-25 | 合肥工业大学 | 淀粉基糊精改性玉米醇溶蛋白纳米颗粒及其制法与应用 |
WO2021077380A1 (zh) * | 2019-10-25 | 2021-04-29 | 合肥工业大学 | 双功能型淀粉基复合纳米颗粒及其制备方法与应用 |
CN113956500A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种玉米醇溶蛋白复合粒子及运载体系、制备方法、应用 |
CN114557440A (zh) * | 2022-02-15 | 2022-05-31 | 江南大学 | 一种玉米醇溶蛋白-甘草酸-壳聚糖稳定的Pickering乳液凝胶及其制备方法 |
CN114886110A (zh) * | 2022-05-30 | 2022-08-12 | 合肥工业大学 | 一种基于淀粉基颗粒-聚合物界面的双层乳液的制备方法 |
-
2023
- 2023-04-06 CN CN202310359592.5A patent/CN116376068B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102573785A (zh) * | 2009-07-27 | 2012-07-11 | 化工产品开发公司Seppic | 具有改善的感官性能的水包油乳液 |
WO2021077380A1 (zh) * | 2019-10-25 | 2021-04-29 | 合肥工业大学 | 双功能型淀粉基复合纳米颗粒及其制备方法与应用 |
CN110917137A (zh) * | 2019-11-26 | 2020-03-27 | 江南大学 | 一种醇溶蛋白纳米颗粒和淀粉纳米颗粒协同稳定的超稳定的皮克林乳液的制备方法 |
CN112120213A (zh) * | 2020-09-23 | 2020-12-25 | 合肥工业大学 | 淀粉基糊精改性玉米醇溶蛋白纳米颗粒及其制法与应用 |
CN113956500A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种玉米醇溶蛋白复合粒子及运载体系、制备方法、应用 |
CN114557440A (zh) * | 2022-02-15 | 2022-05-31 | 江南大学 | 一种玉米醇溶蛋白-甘草酸-壳聚糖稳定的Pickering乳液凝胶及其制备方法 |
CN114886110A (zh) * | 2022-05-30 | 2022-08-12 | 合肥工业大学 | 一种基于淀粉基颗粒-聚合物界面的双层乳液的制备方法 |
Non-Patent Citations (2)
Title |
---|
Preparation, Characteristics, and Advantages of Plant Protein-Based Bioactive Molecule Delivery Systems.foods.2022,全文. * |
大豆蛋白乳液的研究进展;赵妍嫣;卢星星;夏楠;郑志;;食品安全质量检测学报(17);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN116376068A (zh) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Nanostructures of protein-polysaccharide complexes or conjugates for encapsulation of bioactive compounds | |
Xie et al. | Fabrication of ovalbumin/κ-carrageenan complex nanoparticles as a novel carrier for curcumin delivery | |
Chen et al. | Coencapsulation of (−)-Epigallocatechin-3-gallate and quercetin in particle-stabilized W/O/W emulsion gels: Controlled release and bioaccessibility | |
Lu et al. | Development of emulsion gels for the delivery of functional food ingredients: From structure to functionality | |
Miao et al. | Fabrication of polysaccharide-based high internal phase emulsion gels: Enhancement of curcumin stability and bioaccessibility | |
Liu et al. | Tailoring the properties of double-crosslinked emulsion gels using structural design principles: Physical characteristics, stability, and delivery of lycopene | |
Joye et al. | Nanotechnology for increased micronutrient bioavailability | |
Mohammadi et al. | Phytosterols as the core or stabilizing agent in different nanocarriers | |
Jones et al. | Bioavailability of nanotechnology-based bioactives and nutraceuticals | |
Meng et al. | Chitosan-based Pickering emulsion: A comprehensive review on their stabilizers, bioavailability, applications and regulations | |
JP2005517031A (ja) | 水分散性コエンザイムq−10乾燥粉末 | |
Gu et al. | Modulation of lipid digestion profiles using filled egg white protein microgels | |
Cheng et al. | Impact of polysaccharide mixtures on the formation, stability and EGCG loading of water-in-oil high internal phase emulsions | |
Hao et al. | The improvement of the physicochemical properties and bioaccessibility of lutein microparticles by electrostatic complexation | |
CN113966838B (zh) | 一种虾青素纳米结构脂质载体-壳聚糖凝胶微粒及制备方法 | |
Yang et al. | Potential application of polysaccharide mucilages as a substitute for emulsifiers: A review | |
CN115944074A (zh) | Pickering乳状液的制备方法、生物活性物质的包埋递送方法及食品3D打印方法 | |
He et al. | Capsaicin encapsulated in W/O/W double emulsions fabricated via ethanol-induced pectin gelling: Improvement of bioaccessibility and reduction of irritation | |
CN110101084B (zh) | 由蛋黄蛋白肽颗粒稳定的海藻油纳米皮克林乳液与油粉及其制备方法与应用 | |
Li et al. | Preparation and characterization of phytosterol-loaded nanoparticles with sodium caseinate/dextran conjugates | |
Okonkwo et al. | Application of biogels for bioactives delivery: Recent developments and future research insights | |
Artiga-Artigas et al. | Nanostructured systems to increase bioavailability of food ingredients | |
CN116376068B (zh) | 一种植酸交联淀粉-蛋白质复合物协同稳定的双重乳液及在医药领域的应用 | |
Muñoz et al. | Production of food bioactive-loaded nanostructures by microfluidization | |
Zarif et al. | Proteosomes based on milk phospholipids and proteins to enhance the stability and bioaccessibility of β-carotene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |